Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2014

01-11-2014 | Original Article

Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience

Authors: Deniz Peker, Vishwas Parekh, Ravikumar Paluri, Taylor Deal, Uma Borate, Antonio Di Stasi, Shuko Harada, Emmanuel Agosto Arroyo, Vishnu Reddy

Published in: International Journal of Hematology | Issue 5/2014

Login to get access

Abstract

Therapy-related myeloid neoplasms (t-MN) have a common origin in prior cytotoxic therapy and/or radiation. These neoplasms include therapy-related acute myeloid leukemia, myelodysplastic syndrome (t-MDS), and myelodysplastic/myeloproliferative neoplasms (t-MDS/MPN). Myeloid sarcoma (MS), on the other hand, is a rare disease manifesting as an extramedullary collection of immature cells of myeloid lineage. Rarer still is therapy-related MS (t-MS), which has not been adequately studied due to its rarity and its lack of recognition as a unique entity among other t-MN. Here, we report what is to our knowledge the first case series of t-MS, with the aim of investigating and establishing salient clinicopathological and molecular features of this entity.
Literature
1.
Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 439.
2.
Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102(1):43–52 Epub 2003/03/08.PubMedCrossRef
3.
Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137–45 Epub 2010/12/04.PubMedCrossRef
4.
Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. 2013;121(15):2996–3004 Epub 2013/02/16.PubMedCentralPubMedCrossRef
5.
Pedersen-Bjergaard J, Philip P, Pedersen NT, Hou-Jensen K, Svejgaard A, Jensen G, et al. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients. Cancer. 1984;54(3):452–62 Epub 1984/08/01.PubMedCrossRef
6.
Rubin CM, Arthur DC, Woods WG, Lange BJ, Nowell PC, Rowley JD, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood. 1991;78(11):2982–8 Epub 1991/12/01.PubMed
7.
Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 1981;58(4):759–67 Epub 1981/10/01.PubMed
8.
Albain KS, Le Beau MM, Vardiman JW, Golomb HM, Rowley JD. Development of dysmyelopoietic syndrome in a hairy cell leukemia patient treated with chlorambucil: cytogenetic and morphologic evaluation. Cancer Genet Cytogenet. 1983;8(2):107–15 Epub 1983/02/01.PubMedCrossRef
9.
Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84(10):937–45 Epub 1999/10/06.PubMed
10.
Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia. 2002;16(12):2366–78 Epub 2002/11/28.PubMedCrossRef
11.
Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17(4):543–57 Epub 2004/10/21.PubMedCrossRef
12.
Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2005;19(12):2232–40 Epub 2005/11/11.PubMedCrossRef
13.
Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340–50 Epub 2006/12/16.PubMedCrossRef
14.
Zhou J, Bell D, Medeiros LJ. Myeloid sarcoma of the head and neck region. Arch Pathol Lab Med. 2013;137(11):1560–8 Epub 2013/03/28.PubMedCrossRef
15.
Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia cutis. Am J Clin Pathol. 2008;129(1):130–42 Epub 2007/12/20.PubMedCrossRef
16.
Davey FR, Olson S, Kurec AS, Eastman-Abaya R, Gottlieb AJ, Mason DY. The immunophenotyping of extramedullary myeloid cell tumors in paraffin-embedded tissue sections. Am J Surg Pathol. 1988;12(9):699–707 Epub 1988/09/01.PubMedCrossRef
17.
Dusenbery KE, Howells WB, Arthur DC, Alonzo T, Lee JW, Kobrinsky N, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol. 2003;25(10):760–8 Epub 2003/10/07.PubMedCrossRef
18.
Cankaya H, Ugras S, Dilek I. Head and neck granulocytic sarcoma with acute myeloid leukemia: three rare cases. Ear Nose Throat J. 2001;80(4):224–6, 8–9. Epub 2001/05/08.
19.
Suzer T, Colakoglu N, Cirak B, Keskin A, Coskun E, Tahta K. Intracerebellar granulocytic sarcoma complicating acute myelogenous leukemia: a case report and review of the literature. J Clin Neurosci Off J Neurosurg Soc Aust. 2004;11(8):914–7 Epub 2004/11/03.
20.
Bolaman Z, Kadikoylu G, Kafkas S, Kacar F. Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism. Leukemia Lymphoma. 2004;45(6):1285–7 Epub 2004/09/14.PubMedCrossRef
21.
Hancock JC, Prchal JT, Bennett JM, Listinsky CM. Trilineage extramedullary myeloid cell tumor in myelodysplastic syndrome. Arch Pathol Lab Med. 1997;121(5):520–3 Epub 1997/05/01.PubMed
22.
Suh YK, Shin HJ. Fine-needle aspiration biopsy of granulocytic sarcoma: a clinicopathologic study of 27 cases. Cancer. 2000;90(6):364–72 Epub 2001/01/13.PubMedCrossRef
23.
Imamura T, Matsuo S, Yoshihara T, Chiyonobu T, Mori K, Ishida H, et al. Granulocytic sarcoma presenting with severe adenopathy (cervical lymph nodes, tonsils, and adenoids) in a child with juvenile myelomonocytic leukemia and successful treatment with allogeneic bone marrow transplantation. Int J Hematol. 2004;80(2):186–9 Epub 2004/10/16.PubMedCrossRef
24.
Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and therapeutic options. Therap Adv Hematol. 2011;2(5):309–16 Epub 2011/10/01.CrossRef
25.
Bhatta S, Kut V, Petronic-Rosic V, Hyjek E, Larson RA. Therapy-related myeloid sarcoma with an NPM1 mutation. Leukemia Lymphoma. 2010;51(11):2130–1 Epub 2010/09/23.PubMedCrossRef
26.
Brickler MM, Basel DG, Gheorghe G, Margolis DM, Kelly ME, Ehrhardt MJ. Early therapy-related myeloid sarcoma and deletion of 9q22.32 to q31.1. Pediatr Blood Cancer. 2014 (Epub 2014/03/29).
27.
Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res. 1992;16(11):1113–23 Epub 1992/11/01.PubMedCrossRef
28.
Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65(6):1364–72 Epub 1985/06/01.PubMed
29.
Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007;127(2):197–205 Epub 2007/01/11.PubMedCrossRef
30.
Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(12):2510–1 Epub 2004/06/16.CrossRef
31.
Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol. 2009;132(3):410–25 Epub 2009/08/19.PubMedCrossRef
32.
Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785–93 Epub 2011/07/29.PubMedCrossRef
33.
Chen WY, Wang CW, Chang CH, Liu HH, Lan KH, Tang JL, et al. Clinicopathologic features and responses to radiotherapy of myeloid sarcoma. Radiat Oncol. 2013;8:245 Epub 2013/10/24.PubMedCentralPubMedCrossRef
34.
Yilmaz AF, Saydam G, Sahin F, Baran Y. Granulocytic sarcoma: a systematic review. Am J Blood Res. 2013;3(4):265–70 Epub 2014/01/08.PubMedCentralPubMed
35.
Sakai T, Tamura S, Miyoshi T, Nesumi N, Nagai K, Oshima K. Development of myeloid sarcoma after long-term methotrexate use for rheumatoid arthritis. Int J Hematol. 2014;99(4):493–8 Epub 2014/02/08.PubMedCrossRef
36.
Yamauchi K, Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer. 2002;94(6):1739–46 Epub 2002/03/29.PubMedCrossRef
37.
Imrie KR, Kovacs MJ, Selby D, Lipton J, Patterson BJ, Pantalony D, et al. Isolated chloroma: the effect of early antileukemic therapy. Ann Intern Med. 1995;123(5):351–3 Epub 1995/09/01.PubMedCrossRef
38.
Chevallier P, Labopin M, Cornelissen J, Socie G, Rocha V, Mohty M, et al. Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Haematologica. 2011;96(9):1391–4 Epub 2011/06/21.PubMedCentralPubMedCrossRef
39.
Antic D, Elezovic I, Milic N, Suvajdzic N, Vidovic A, Perunicic M, et al. Is there a “gold” standard treatment for patients with isolated myeloid sarcoma? Biomed Pharmacother. 2013;67(1):72–7 Epub 2012/12/12.PubMedCrossRef
40.
Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Isidori A, et al. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leukemia Lymphoma. 2004;45(9):1791–5 Epub 2004/06/30.PubMedCrossRef
41.
Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs. 2011;20(10):1377–95 Epub 2011/09/08.PubMedCrossRef
42.
Yu J, Peng Y, Wu LC, Xie Z, Deng Y, Hughes T, et al. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PloS one. 2013;8(2):e55934. Epub 2013/03/05.
43.
Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, Eckhardt SG. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia. 2007;21(4):739–46 Epub 2007/02/03.PubMed
Metadata
Title
Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience
Authors
Deniz Peker
Vishwas Parekh
Ravikumar Paluri
Taylor Deal
Uma Borate
Antonio Di Stasi
Shuko Harada
Emmanuel Agosto Arroyo
Vishnu Reddy
Publication date
01-11-2014
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1659-y

Other articles of this Issue 5/2014

International Journal of Hematology 5/2014 Go to the issue

Case Report

Anti-erythropoietin receptor antibody-associated pure red cell aplasia accompanied by Coombs-negative autoimmune hemolytic anemia in a patient with T cell/histiocyte-rich large B cell lymphoma

Case Report

Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation

Rapid Communication

Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy

Case Report

Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation

Original Article

Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan

Images in Hematology

Crossed cerebellar diaschisis due to cerebral diffuse large B cell lymphoma on 18F-FDG PET/CT
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits